Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $184.58M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.21
• Revenue Growth: -19.00%
• EPS Growth: -2.72%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 96,637,200
• 10 Day Avg. Volume: 1,354,975
• 30 Day Avg. Volume: 1,199,069
• PEG Ratio: 0.28
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 13.31
• P/FCF Ratio: -1.32
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 17.87
• Enterprise Value/Gross Profit: 20.26
• Enterprise Value/Ebitda: -1.53
• 1Y Price Target: $8.75
• Price Target Upside: 358.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -1.34
• Revenue Forecast (FY): $21.44M

• Rating: 45 Neutral
• Price Target: $2.00 ▲(4.71% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is primarily constrained by weak financial performance, including a 2025 revenue collapse, persistent large losses, and significant ongoing cash burn with declining equity. Technical indicators are neutral-to-mixed and provide only limited support, while valuation is not compelling due to negative earnings and no dividend.

Positive Factors

Proprietary platform

Caribou’s proprietary chRDNA CRISPR platform is a durable competitive asset: it underpins multiple allogeneic CAR-T/CAR-NK programs, supports partner collaborations, and can enable scalable off-the-shelf cell therapies if clinical and manufacturing hurdles are cleared, sustaining strategic value over months.

Negative Factors

Revenue collapse

A precipitous drop to essentially zero revenue in 2025 signals a severe deterioration in partner payments or grant activity and removes near-term operating revenue support. This materially weakens visibility into sustainable cash inflows and strains the company’s ability to fund R&D without external financing.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. I...

Read more

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. I...

How the Company Makes Money

Caribou Biosciences primarily makes money through (1) collaboration and license revenue and (2) government/other grant revenue, with the potential for future product sales if its therapy candidates receive regulatory approval. 1) Collaboration an...

Read more

Caribou Biosciences primarily makes money through (1) collaboration and license revenue and (2) government/other grant revenue, with the potential for future product sales if its therapy candidates receive regulatory approval. 1) Collaboration an...

Caribou Biosciences Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.16M	9.99M	34.48M	13.85M	9.60M
Gross Profit	7.51M	6.07M	30.95M	10.21M	8.61M
EBITDA	-132.55M	-162.69M	-112.53M	-95.71M	-65.61M
Net Income	-148.13M	-149.10M	-102.07M	-99.42M	-66.92M
Balance Sheet
Total Assets	175.37M	313.31M	432.21M	373.76M	442.36M
Cash, Cash Equivalents and Short-Term Investments	139.34M	209.54M	328.83M	247.66M	375.83M
Total Debt	27.23M	26.49M	27.11M	27.75M	259.00K
Total Liabilities	53.19M	60.36M	63.81M	72.89M	54.53M
Stockholders Equity	122.17M	252.95M	368.40M	300.87M	387.82M
Cash Flow
Free Cash Flow	-112.35M	-144.71M	-104.90M	-97.42M	-35.64M
Operating Cash Flow	-110.99M	-138.20M	-93.29M	-90.97M	-32.52M
Investing Cash Flow	102.24M	86.61M	-68.18M	-93.25M	-176.40M
Financing Cash Flow	4.82M	16.72M	154.30M	2.13M	433.43M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Positive. The current price of 1.91 is above the 20-day moving average (MA) of 1.88, above the 50-day MA of 1.72, and above the 200-day MA of 1.86, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 53.76 is Neutral, neither overbought nor oversold. The STOCH value of 44.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMO	51 Neutral	$127.90M	-1.47	-813.95%	―	-37.13%	40.47%
CABA	50 Neutral	$313.93M	-1.34	-107.14%	―	―	-17.21%
ELTX	50 Neutral	$199.05M	-3.95	-977.67%	―	―	17.36%
VOR	50 Neutral	$563.42M	-0.10	274.58%	―	―	-1072.48%
CRBU	45 Neutral	$184.58M	-1.42	-74.28%	―	-19.00%	-2.72%
CLLS	45 Neutral	$237.90M	-7.16	-69.63%	―	158.54%	66.90%